| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 30 | 2024 | 691 | 2.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 25 | 2024 | 356 | 2.090 |
Why?
|
| Ovarian Neoplasms | 12 | 2022 | 61 | 1.530 |
Why?
|
| Pneumonectomy | 13 | 2022 | 88 | 1.030 |
Why?
|
| Biomarkers, Tumor | 10 | 2015 | 217 | 0.780 |
Why?
|
| Neoplasm Staging | 19 | 2024 | 404 | 0.630 |
Why?
|
| Interleukin-16 | 5 | 2022 | 7 | 0.590 |
Why?
|
| Female | 53 | 2024 | 16983 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2017 | 230 | 0.450 |
Why?
|
| Chickens | 11 | 2021 | 32 | 0.440 |
Why?
|
| Postoperative Complications | 8 | 2022 | 991 | 0.410 |
Why?
|
| Aged | 36 | 2024 | 10048 | 0.400 |
Why?
|
| Middle Aged | 35 | 2024 | 10195 | 0.400 |
Why?
|
| Adenocarcinoma | 5 | 2018 | 206 | 0.390 |
Why?
|
| Disease Models, Animal | 10 | 2021 | 782 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2017 | 337 | 0.360 |
Why?
|
| Male | 39 | 2024 | 16445 | 0.350 |
Why?
|
| Prognosis | 15 | 2019 | 919 | 0.340 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 3 | 2015 | 14 | 0.340 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2015 | 69 | 0.320 |
Why?
|
| Humans | 50 | 2024 | 30997 | 0.320 |
Why?
|
| Ovary | 3 | 2021 | 19 | 0.320 |
Why?
|
| Retrospective Studies | 20 | 2022 | 3658 | 0.320 |
Why?
|
| Cachexia | 2 | 2019 | 14 | 0.310 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 45 | 0.300 |
Why?
|
| Contrast Media | 4 | 2016 | 136 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 4 | 2011 | 78 | 0.280 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2016 | 35 | 0.280 |
Why?
|
| Aged, 80 and over | 18 | 2022 | 5189 | 0.270 |
Why?
|
| Body Composition | 2 | 2024 | 67 | 0.270 |
Why?
|
| Adult | 22 | 2022 | 8931 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2018 | 112 | 0.250 |
Why?
|
| Thoracic Surgery | 2 | 2022 | 32 | 0.240 |
Why?
|
| Biomarkers | 6 | 2018 | 733 | 0.240 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2015 | 14 | 0.230 |
Why?
|
| Ultrasonography | 6 | 2021 | 271 | 0.230 |
Why?
|
| Gene Expression | 3 | 2022 | 239 | 0.220 |
Why?
|
| Survival Analysis | 8 | 2019 | 320 | 0.210 |
Why?
|
| Image Enhancement | 2 | 2014 | 60 | 0.210 |
Why?
|
| Survival Rate | 8 | 2021 | 404 | 0.210 |
Why?
|
| Cannabinoids | 1 | 2022 | 3 | 0.210 |
Why?
|
| Endometriosis | 1 | 2022 | 6 | 0.210 |
Why?
|
| Registries | 2 | 2021 | 203 | 0.200 |
Why?
|
| Treatment Outcome | 12 | 2019 | 3806 | 0.200 |
Why?
|
| Animals | 12 | 2021 | 4723 | 0.200 |
Why?
|
| MicroRNAs | 1 | 2022 | 47 | 0.200 |
Why?
|
| Oviducts | 1 | 2021 | 1 | 0.200 |
Why?
|
| Quinazolines | 3 | 2012 | 27 | 0.190 |
Why?
|
| Risk Assessment | 9 | 2019 | 718 | 0.190 |
Why?
|
| Cytodiagnosis | 1 | 2021 | 18 | 0.190 |
Why?
|
| Urine | 1 | 2021 | 10 | 0.190 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2021 | 14 | 0.190 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2021 | 28 | 0.180 |
Why?
|
| DNA Methylation | 2 | 2012 | 134 | 0.180 |
Why?
|
| Algorithms | 6 | 2014 | 414 | 0.180 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 1922 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2012 | 260 | 0.170 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2018 | 19 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 3 | 2015 | 64 | 0.170 |
Why?
|
| Autoantibodies | 2 | 2010 | 103 | 0.170 |
Why?
|
| Body Mass Index | 2 | 2024 | 452 | 0.170 |
Why?
|
| Gases | 1 | 2019 | 7 | 0.170 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 341 | 0.160 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2018 | 3 | 0.160 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 208 | 0.160 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2021 | 41 | 0.160 |
Why?
|
| Carcinogenesis | 1 | 2018 | 26 | 0.160 |
Why?
|
| Carcinoma | 2 | 2021 | 64 | 0.160 |
Why?
|
| Predictive Value of Tests | 7 | 2014 | 549 | 0.160 |
Why?
|
| Lymphatic Metastasis | 4 | 2012 | 104 | 0.150 |
Why?
|
| Proportional Hazards Models | 6 | 2017 | 368 | 0.150 |
Why?
|
| Immunohistochemistry | 6 | 2016 | 430 | 0.150 |
Why?
|
| Mucous Membrane | 1 | 2018 | 46 | 0.150 |
Why?
|
| Macrophages | 1 | 2018 | 137 | 0.150 |
Why?
|
| Esophageal Neoplasms | 1 | 2018 | 49 | 0.150 |
Why?
|
| Thyrotropin | 1 | 2017 | 13 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 82 | 0.150 |
Why?
|
| Thyroxine | 1 | 2017 | 27 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 79 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2017 | 32 | 0.140 |
Why?
|
| Pulmonary Diffusing Capacity | 3 | 2016 | 10 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2017 | 14 | 0.140 |
Why?
|
| Cohort Studies | 8 | 2019 | 2043 | 0.140 |
Why?
|
| Heart Failure | 2 | 2012 | 219 | 0.140 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 33 | 0.140 |
Why?
|
| Carbon Monoxide | 2 | 2022 | 9 | 0.140 |
Why?
|
| Lymphoma | 1 | 2017 | 46 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2015 | 190 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2016 | 9 | 0.140 |
Why?
|
| Thoracic Wall | 1 | 2016 | 11 | 0.130 |
Why?
|
| Ribs | 1 | 2016 | 18 | 0.130 |
Why?
|
| Metformin | 1 | 2016 | 24 | 0.130 |
Why?
|
| Young Adult | 7 | 2017 | 2063 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2012 | 24 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 60 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 192 | 0.130 |
Why?
|
| Ultrasonics | 1 | 2015 | 17 | 0.130 |
Why?
|
| Disease Progression | 6 | 2016 | 830 | 0.120 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 8 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 8 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 54 | 0.120 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 9 | 0.120 |
Why?
|
| Hepatitis B | 1 | 2014 | 20 | 0.120 |
Why?
|
| Vaccination | 1 | 2014 | 48 | 0.120 |
Why?
|
| Cytokines | 2 | 2014 | 351 | 0.120 |
Why?
|
| Integrin alpha5 | 1 | 2014 | 1 | 0.120 |
Why?
|
| Molecular Probes | 1 | 2014 | 2 | 0.120 |
Why?
|
| Integrin beta3 | 1 | 2014 | 7 | 0.120 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2014 | 23 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2013 | 17 | 0.110 |
Why?
|
| Risk Factors | 5 | 2022 | 2588 | 0.110 |
Why?
|
| Scapula | 1 | 2014 | 84 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2013 | 63 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2014 | 90 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 135 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 95 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 213 | 0.110 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 10 | 0.110 |
Why?
|
| Genes, p16 | 1 | 2012 | 5 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 87 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 57 | 0.110 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2013 | 11 | 0.110 |
Why?
|
| Interleukin-2 | 1 | 2012 | 69 | 0.100 |
Why?
|
| Immunoassay | 1 | 2012 | 45 | 0.100 |
Why?
|
| Adolescent | 5 | 2022 | 2401 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 43 | 0.100 |
Why?
|
| Cross-Sectional Studies | 4 | 2017 | 1009 | 0.100 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2012 | 21 | 0.100 |
Why?
|
| Melanoma | 1 | 2012 | 54 | 0.100 |
Why?
|
| Antigens, Neoplasm | 2 | 2010 | 46 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 69 | 0.100 |
Why?
|
| C-Peptide | 1 | 2011 | 8 | 0.100 |
Why?
|
| ErbB Receptors | 4 | 2018 | 81 | 0.100 |
Why?
|
| Hospitalization | 2 | 2012 | 336 | 0.100 |
Why?
|
| Fluorocarbons | 1 | 2011 | 17 | 0.090 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 386 | 0.090 |
Why?
|
| Albumins | 1 | 2011 | 37 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2021 | 1897 | 0.090 |
Why?
|
| Hematologic Tests | 1 | 2010 | 7 | 0.090 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 11 | 0.090 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2010 | 7 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 10 | 0.090 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2010 | 20 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 17 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2010 | 36 | 0.090 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 41 | 0.080 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2010 | 107 | 0.080 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2008 | 3 | 0.080 |
Why?
|
| Genes, erbB-2 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2009 | 74 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2021 | 354 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2009 | 81 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1311 | 0.080 |
Why?
|
| Body Weight | 2 | 2024 | 141 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 36 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 35 | 0.080 |
Why?
|
| Area Under Curve | 3 | 2014 | 70 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2008 | 26 | 0.080 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 295 | 0.080 |
Why?
|
| Depression | 1 | 2012 | 481 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 91 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2007 | 8 | 0.070 |
Why?
|
| Menisci, Tibial | 1 | 2009 | 187 | 0.070 |
Why?
|
| Weight Loss | 2 | 2019 | 117 | 0.070 |
Why?
|
| Chicago | 3 | 2017 | 943 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 818 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 275 | 0.070 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 207 | 0.070 |
Why?
|
| Lung | 2 | 2022 | 173 | 0.070 |
Why?
|
| Aging | 2 | 2022 | 1727 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 376 | 0.060 |
Why?
|
| Incidence | 2 | 2021 | 785 | 0.060 |
Why?
|
| Proteomics | 2 | 2018 | 96 | 0.060 |
Why?
|
| ROC Curve | 2 | 2014 | 145 | 0.060 |
Why?
|
| Bronchoscopy | 2 | 2016 | 30 | 0.050 |
Why?
|
| Sex Factors | 2 | 2019 | 511 | 0.050 |
Why?
|
| Illinois | 2 | 2014 | 267 | 0.050 |
Why?
|
| Receptors, Cannabinoid | 1 | 2022 | 1 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2022 | 22 | 0.050 |
Why?
|
| Mutation | 2 | 2018 | 409 | 0.050 |
Why?
|
| PAX2 Transcription Factor | 1 | 2021 | 1 | 0.050 |
Why?
|
| WT1 Proteins | 1 | 2021 | 2 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2014 | 300 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2022 | 164 | 0.050 |
Why?
|
| Referral and Consultation | 2 | 2014 | 91 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 1672 | 0.050 |
Why?
|
| Gene Dosage | 2 | 2012 | 25 | 0.050 |
Why?
|
| Etoposide | 2 | 2011 | 53 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 91 | 0.040 |
Why?
|
| Carboplatin | 2 | 2011 | 50 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 817 | 0.040 |
Why?
|
| Paclitaxel | 2 | 2011 | 76 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2011 | 324 | 0.040 |
Why?
|
| Carcinoma, Small Cell | 2 | 2010 | 73 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 226 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2010 | 35 | 0.040 |
Why?
|
| Superoxide Dismutase | 1 | 2018 | 20 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 426 | 0.040 |
Why?
|
| Age Factors | 2 | 2012 | 873 | 0.040 |
Why?
|
| Sarcopenia | 1 | 2019 | 34 | 0.040 |
Why?
|
| Cell Movement | 1 | 2018 | 105 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 583 | 0.040 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 17 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2019 | 191 | 0.040 |
Why?
|
| Growth Charts | 1 | 2017 | 2 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2017 | 9 | 0.040 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 9 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 32 | 0.040 |
Why?
|
| Immunity | 1 | 2017 | 26 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 50 | 0.030 |
Why?
|
| Microbubbles | 1 | 2016 | 9 | 0.030 |
Why?
|
| Pediatric Obesity | 1 | 2017 | 48 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2016 | 31 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 67 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 12 | 0.030 |
Why?
|
| Thoracotomy | 1 | 2016 | 25 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2016 | 26 | 0.030 |
Why?
|
| Neoplasms | 1 | 2019 | 261 | 0.030 |
Why?
|
| Microvessels | 1 | 2015 | 17 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2015 | 41 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2017 | 689 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 178 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 11 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 16 | 0.030 |
Why?
|
| Minnesota | 1 | 2014 | 10 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2016 | 99 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 150 | 0.030 |
Why?
|
| United States | 1 | 2021 | 2375 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2014 | 74 | 0.030 |
Why?
|
| Length of Stay | 1 | 2016 | 339 | 0.030 |
Why?
|
| Poultry Diseases | 1 | 2013 | 3 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 407 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 156 | 0.030 |
Why?
|
| Chemokine CCL3 | 1 | 2013 | 14 | 0.030 |
Why?
|
| Granuloma | 1 | 2013 | 15 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 17 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 24 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 500 | 0.030 |
Why?
|
| Child | 1 | 2017 | 1430 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2012 | 29 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2013 | 39 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2013 | 112 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2012 | 78 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 52 | 0.030 |
Why?
|
| Pneumonia | 1 | 2013 | 75 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 442 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 234 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 11 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 67 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 99 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 11 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 28 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 695 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 11 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2010 | 4 | 0.020 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2010 | 5 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2010 | 7 | 0.020 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2010 | 7 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 41 | 0.020 |
Why?
|
| CpG Islands | 1 | 2010 | 36 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 37 | 0.020 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2010 | 18 | 0.020 |
Why?
|
| Medical Records | 1 | 2010 | 34 | 0.020 |
Why?
|
| Forced Expiratory Volume | 1 | 2009 | 10 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 81 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 55 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2010 | 101 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 80 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 27 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2009 | 76 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2012 | 498 | 0.020 |
Why?
|
| Body Height | 1 | 2009 | 34 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 272 | 0.020 |
Why?
|
| Prosthesis Fitting | 1 | 2009 | 24 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2010 | 89 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 119 | 0.020 |
Why?
|
| Models, Anatomic | 1 | 2009 | 54 | 0.020 |
Why?
|
| Cause of Death | 1 | 2009 | 68 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 107 | 0.020 |
Why?
|
| Cisplatin | 1 | 2009 | 95 | 0.020 |
Why?
|
| Smoking | 1 | 2010 | 197 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 135 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2008 | 3 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2008 | 24 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2008 | 43 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 99 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 6 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2008 | 6 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2008 | 52 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2009 | 144 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 105 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2010 | 662 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2008 | 59 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2008 | 204 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2007 | 4 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2008 | 54 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 42 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 60 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 168 | 0.020 |
Why?
|
| Communication | 1 | 2007 | 120 | 0.020 |
Why?
|
| Logistic Models | 1 | 2007 | 409 | 0.020 |
Why?
|
| Reoperation | 1 | 2008 | 950 | 0.010 |
Why?
|